PL3506904T3 - Leczenie otępienia - Google Patents
Leczenie otępieniaInfo
- Publication number
- PL3506904T3 PL3506904T3 PL17761842T PL17761842T PL3506904T3 PL 3506904 T3 PL3506904 T3 PL 3506904T3 PL 17761842 T PL17761842 T PL 17761842T PL 17761842 T PL17761842 T PL 17761842T PL 3506904 T3 PL3506904 T3 PL 3506904T3
- Authority
- PL
- Poland
- Prior art keywords
- dementia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
EP17761842.8A EP3506904B1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3506904T3 true PL3506904T3 (pl) | 2021-07-26 |
Family
ID=57139937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17761842T PL3506904T3 (pl) | 2016-09-01 | 2017-08-25 | Leczenie otępienia |
Country Status (18)
Country | Link |
---|---|
US (1) | US10842796B2 (pl) |
EP (1) | EP3506904B1 (pl) |
JP (1) | JP7066679B2 (pl) |
KR (1) | KR102559354B1 (pl) |
CN (1) | CN109890391B (pl) |
AU (1) | AU2017318333B2 (pl) |
CA (1) | CA3034625A1 (pl) |
DK (1) | DK3506904T3 (pl) |
ES (1) | ES2847929T3 (pl) |
GB (1) | GB201614834D0 (pl) |
HR (1) | HRP20210162T1 (pl) |
MX (1) | MX2019002429A (pl) |
MY (1) | MY187564A (pl) |
PL (1) | PL3506904T3 (pl) |
PT (1) | PT3506904T (pl) |
SG (1) | SG11201901125TA (pl) |
SI (1) | SI3506904T1 (pl) |
WO (1) | WO2018041739A1 (pl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
AU2019308873A1 (en) | 2018-07-26 | 2021-02-04 | Wista Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
JP7401531B2 (ja) | 2018-09-05 | 2023-12-19 | ゲンティング タークス ダイアグノースティク センター エスディエヌ ビーエイチディ | 神経変性疾患のためのネットワーク法 |
GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
MXPA04011762A (es) * | 2002-05-31 | 2005-03-31 | Lundbeck & Co As H | Una combinacion de antagonista de nmda e inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer. |
WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
CN101460222B (zh) * | 2006-03-29 | 2013-12-04 | 维斯塔实验室有限公司 | 锍化合物及其用途 |
CN104119294B (zh) * | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
SI2167095T1 (sl) * | 2007-06-19 | 2019-09-30 | Wista Laboratories Ltd. | Fenotiazinske spojine za zdravljenje blage kognitivne motnje |
EP2954932B1 (en) * | 2007-10-03 | 2018-09-19 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
PT2480541E (pt) | 2009-09-24 | 2016-01-26 | Wista Lab Ltd | Hidratos de cloreto de metiltiónio cristalino (azul de metileno) |
EP2480540B1 (en) * | 2009-09-24 | 2017-11-29 | WisTa Laboratories Ltd. | Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof |
SI2673266T1 (sl) | 2011-02-11 | 2016-11-30 | Wista Laboratories Ltd. | Fenotiazin diaminijeve soli in njihova uporaba |
CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en active Application Filing
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active IP Right Grant
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 MX MX2019002429A patent/MX2019002429A/es unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
-
2021
- 2021-02-01 HR HRP20210162TT patent/HRP20210162T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT3506904T (pt) | 2021-02-02 |
CA3034625A1 (en) | 2018-03-08 |
US10842796B2 (en) | 2020-11-24 |
CN109890391A (zh) | 2019-06-14 |
SI3506904T1 (sl) | 2021-03-31 |
DK3506904T3 (da) | 2021-01-04 |
EP3506904B1 (en) | 2020-12-09 |
JP7066679B2 (ja) | 2022-05-13 |
AU2017318333B2 (en) | 2023-05-11 |
KR102559354B1 (ko) | 2023-07-26 |
ES2847929T3 (es) | 2021-08-04 |
SG11201901125TA (en) | 2019-03-28 |
JP2019526571A (ja) | 2019-09-19 |
AU2017318333A1 (en) | 2019-04-18 |
WO2018041739A1 (en) | 2018-03-08 |
EP3506904A1 (en) | 2019-07-10 |
GB201614834D0 (en) | 2016-10-19 |
MY187564A (en) | 2021-09-30 |
KR20190045273A (ko) | 2019-05-02 |
HRP20210162T1 (hr) | 2021-03-19 |
CN109890391B (zh) | 2023-01-31 |
MX2019002429A (es) | 2019-07-08 |
US20190192530A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006746B (en) | Methods of treatment | |
EP3483284C0 (en) | NANOVESICLES DERIVED FROM BACTERIA OF THE GENREPROPIONIBACTERIUM | |
GB201701673D0 (en) | Methods of well treatment | |
IL279627A (en) | A method for treating depression | |
PL3506904T3 (pl) | Leczenie otępienia | |
GB201608885D0 (en) | Treatment | |
IL290855A (en) | Treatment methods using vitamin d | |
GB201410116D0 (en) | Method of treatment | |
PL3377064T3 (pl) | Orwepitant do leczenia przewlekłego kaszlu | |
IL253028B (en) | treatment method | |
GB201416832D0 (en) | Methods of treatment | |
LT3504163T (lt) | Nuotekų valymas | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
GB201602802D0 (en) | Method of treatment | |
IL260094A (en) | Treatment of hand eczema | |
GB201412010D0 (en) | Treatment of hypertransaminasemia | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
GB201512139D0 (en) | Methods of treatment | |
GB201510870D0 (en) | Treatment of infarction | |
GB201608599D0 (en) | Treatment of opioid tollerence | |
GB201617107D0 (en) | Treatment | |
GB201613350D0 (en) | Treatment of hyperpigmentation | |
GB201612260D0 (en) | Treatment | |
GB201612193D0 (en) | Treatment | |
GB201609683D0 (en) | Treatment |